Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ANVS logo ANVS
Upturn stock ratingUpturn stock rating
ANVS logo

Annovis Bio Inc (ANVS)

Upturn stock ratingUpturn stock rating
$1.47
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

04/22/2025: ANVS (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $14.25

1 Year Target Price $14.25

Analysts Price Target For last 52 week
$14.25Target price
Low$1.11
Current$1.47
high$17.88

Analysis of Past Performance

Type Stock
Historic Profit -93.24%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 04/22/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 42.29M USD
Price to earnings Ratio -
1Y Target Price 14.25
Price to earnings Ratio -
1Y Target Price 14.25
Volume (30-day avg) 4
Beta 1.62
52 Weeks Range 1.11 - 17.88
Updated Date 06/30/2025
52 Weeks Range 1.11 - 17.88
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.37

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -91.05%
Return on Equity (TTM) -280.78%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 20048946
Price to Sales(TTM) -
Enterprise Value 20048946
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.57
Shares Outstanding 19486200
Shares Floating 15624645
Shares Outstanding 19486200
Shares Floating 15624645
Percent Insiders 14.69
Percent Institutions 16.03

Analyst Ratings

Rating 1
Target Price 14.25
Buy 1
Strong Buy 2
Buy 1
Strong Buy 2
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Annovis Bio Inc

stock logo

Company Overview

overview logo History and Background

Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegenerative diseases. Founded in 2008, it focuses on developing therapies for Alzheimer's, Parkinson's, and other related disorders. It has evolved from early research to clinical trials.

business area logo Core Business Areas

  • Drug Development: Development of therapeutics for neurodegenerative diseases, focusing on protein translation inhibitors to reduce toxic proteins.

leadership logo Leadership and Structure

Maria L. Maccecchini is the President and CEO. The company has a board of directors and a management team focused on clinical development and research.

Top Products and Market Share

overview logo Key Offerings

  • Buntanetap (ANVS401): Buntanetap is Annovis Bio's lead drug candidate, a translation inhibitor targeting multiple toxic proteins, including amyloid-beta, tau, and alpha-synuclein. Currently in clinical development for Alzheimer's and Parkinson's disease. Market share is currently negligible as it is not approved yet. Competitors include large pharmaceutical companies with marketed Alzheimer's and Parkinson's drugs.

Market Dynamics

industry overview logo Industry Overview

The neurodegenerative disease market is large and growing, with significant unmet medical needs, especially in Alzheimer's and Parkinson's. There is increasing investment in research and development.

Positioning

Annovis Bio is a smaller player focused on a novel approach of inhibiting protein translation. It aims to differentiate itself through its multi-target mechanism and potential to address multiple neurodegenerative diseases.

Total Addressable Market (TAM)

The global Alzheimer's disease market is expected to reach hundreds of billions of dollars. Annovis Bio is positioned to potentially capture a small but significant share if Buntanetap is approved.

Upturn SWOT Analysis

Strengths

  • Novel multi-target mechanism
  • Potential to address multiple neurodegenerative diseases
  • Promising early clinical data

Weaknesses

  • Limited financial resources
  • High risk of clinical trial failure
  • Reliance on a single drug candidate

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new indications
  • Positive clinical trial results

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • ABBV
  • BIIB
  • VTVT

Competitive Landscape

Annovis Bio faces intense competition from larger pharmaceutical companies with more resources and approved drugs. Its competitive advantage lies in its novel mechanism and multi-target approach, but it carries significant risk due to its reliance on a single drug candidate. ABBV and LLY have the largest market share, followed by BIIB.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been focused on advancing Buntanetap through clinical trials.

Future Projections: Future growth depends on successful clinical trial outcomes and potential partnerships. Analyst projections are speculative and highly dependent on clinical data.

Recent Initiatives: Recent initiatives include advancing Buntanetap in Phase 2 and 3 clinical trials for Alzheimer's and Parkinson's disease.

Summary

Annovis Bio is a high-risk, high-reward clinical-stage company focused on neurodegenerative diseases. Its Buntanetap drug candidate has a novel mechanism that targets multiple toxic proteins. The company faces significant competition and financial challenges but could see substantial gains if its clinical trials are successful. Investors should carefully consider the risks before investing.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Annovis Bio Inc. website
  • SEC filings (10-K, 10-Q)
  • Analyst reports
  • Industry reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Financial data and market information are subject to change. Please consult with a qualified financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Annovis Bio Inc

Exchange NYSE
Headquaters Malvern, PA, United States
IPO Launch date 2010-02-12
Founder, CEO, President & Executive Director Dr. Maria L. Maccecchini Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 8
Full time employees 8

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.